Objectives: Considering the scarcity of data on anaplastic lymphoma kinase (ALK) cancer biomarker, a review of literature was performed to collate information on its prevalence across all common tumor sites, and the estimates of diagnosed incidence of each tumor were used to determine the total number of incident ALK-positive cases for the year 2018 in the United States (US). Conclusions: ALK-mutations are found in multiple tumor sites, and collectively represent 19,800 cases of cancer in 2018 in US. READ ARTICLE
Value in Health DOI:10.1016/j.jval.2019.04.289
Authors: N. J. Zhang